Abstract 39: Frequency of the Angiotensin Converting Enzyme (I/D) and β1 Adrenergic Receptor (Arg389Gly) Gene Polymorphisms in a Sample of Mexican Population
Introduction: The angiotensin converting enzyme (ACE) is involved in blood pressure regulation. The I/D polymorphism of ACE has been associated with hypertension, left ventricular hypertrophy and metabolic syndrome.
The β1 adrenergic receptor (ARβ1) is located mainly in the heart, its activation has a chronotropic and inotropic effect. The Arg389Gly polymorphism of ARβ1 has been associated with dilated cardiomyopathy, atrial fibrillation and vasovagal syncope.
The identification of these polymorphisms in a control group, will reveal the frequencies in healthy mexican population so we can compare with the diseased population and seek association with different diseases.
Objective: Identifying gene and allelic prevalence in a healthy population.
Material and Methods: We worked with 45 samples from healthy individuals, 36 males and 9 females, with a median age of 35.8 ± 16.1 and a BMI of 25.81 ± 4.6.
Extraction of DNA from 10 ml of peripheral blood. ACE polymorphism was determined by direct PCR. The determination of the Arg389Gly polymorphism was by PCR-RFLP.
Results: The gene frequency of the ACE gene in 39 subjects was: DD 33.33% (13 of 39), ID 38.46% (15 of 39) and II 28.2% (11 of 39). The allelic frequency: I 47.43% and D 52.56%.
Arg389Gly polymorphism frequency was in 11 subjects: ArgArg 9% (1 of 11), ArgGly 72.7% (8 of 11) and GlyGly 18.2% (2 of 11). The allele frequency: 45% Arg and Gly 55%.
Conclusions: DD homozygote frequency differs from that observed in the study of Vargas et al., which is lower. This is important because the D allele is associated with greater activity and concentration of ACE, which may predispose to cardiovascular disease in our population.
Regarding the Arg389Gly polymorphism, it has been observed that the Gly allele is linked to cardiovascular disease and the response to beta-blockers.
Our population showed an increase of Gly allele carriers, so they may be more susceptible to these diseases.
It is important to know the frequency of these polymorphisms in our population, and identify that they can impact in medical treatment or may serve as potential predictors of cardiovascular disease.
Author Disclosures: J. Cervantes Minjares: None M. De la Torre Zazueta: None G. Hernández Pacheco: None.
- © 2014 by American Heart Association, Inc.